{"url_path":"/sec/tenx/8-k/2026-06-29/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/34956/0001193125-26-288600-index.html","accession_number":"0001193125-26-288600","cik":"0000034956","ticker":"TENX","issuer_name":"TENAX THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/34956/0001193125-26-288600-index.html","primary_entity_key":"0000034956","primary_entity_name":"TENAX THERAPEUTICS, INC."},"word_count":120,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits.\n\n \n\nExhibit\nNo.\n  \nDescription\n\n10.1\n  \n[Amendment No. 1 to Employment Agreement, by and between Tenax Therapeutics, Inc. and Christopher Giordano](d251626dex101.htm)\n\n10.2\n  \n[Amendment No. 1 to Employment Agreement, by and between Tenax Therapeutics, Inc. and Thomas Staab](d251626dex102.htm)\n\n10.3\n  \n[Amendment No. 3 to Employment Agreement, by and between Tenax Therapeutics, Inc. and Stuart Rich](d251626dex103.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nTENAX THERAPEUTICS, INC.\n\nBy:\n \n\n/s Christopher Giordano\n\nName:\n \nChristopher Giordano\n\nTitle:\n \nChief Executive Officer\n\nDate:\n \nJune 29, 2026"}